P. Miner

P. Miner, H. Proskin, S. Rodriguez-Stanley, 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

CASE REPORT: Pheasant-Induced Dysphagia

M. Robinson, P. Miner, S. Rodriguez-Stanley, 2000, Digestive Diseases and Sciences.

Esophageal reflux in conditioned runners, cyclists, and weightlifters.

M. Bemben, P. Miner, S. Rodriguez-Stanley, 2003, Medicine and science in sports and exercise.

Pancreatitis and gold treatment of rheumatoid arthritis.

P. Miner, J. Fleming, A. Eisemann, 1989, Annals of internal medicine.

Terminal ileal mucosal mast cells in irritable bowel syndrome

A. Weston, P. Miner, W. Biddle, 1993, Digestive Diseases and Sciences.

Intravenous esomeprazole 40 mg vs. intravenous lansoprazole 30 mg for controlling intragastric acidity in healthy adults

J. Pisegna, M. Sostek, P. Miner, 2007, Alimentary pharmacology & therapeutics.

Calcium Carbonate Antacids Alter Esophageal Motility in Heartburn Sufferers

M. Mellow, P. Miner, H. Akbarali, 2004, Digestive Diseases and Sciences.

The role of the mast cell in clinical gastrointestinal disease with special reference to systemic mastocytosis.

P. Miner, 1991, The Journal of investigative dermatology.

SAFETY AND ACTIVITY EVALUATION OF rhlL‐11 IN SUBJECTS WITH ACTIVE CROHN'S DISEASE.: 520

A. Buchman, S. Hanauer, B. Sands, 1997 .

Reanalysis of Intragastric pH Results Based on Updated Correction Factors for Slimline® and Zinetics™ 24 Single-Use pH Catheters

Yusong Chen, M. Sostek, P. Katz, 2006, The American Journal of Gastroenterology.

Prucalopride induces high‐amplitude propagating contractions in the colon of patients with chronic constipation: a randomized study

M. Camilleri, D. Burton, B. Mellgård, 2016, Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society.

Evaluation of antral mast cells in nonulcer dyspepsia

P. Miner, S. E. Matter, P. Bhatia, 1990, Digestive Diseases and Sciences.

An enema formulation of alicaforsen, an antisense inhibitor of intercellular adhesion molecule‐1, in the treatment of chronic, unremitting pouchitis

P. Miner, B. Bane, M. Wedel, 2004, Alimentary pharmacology & therapeutics.

Prucalopride (PRU) significantly improves symptoms (SX) associated with chronic constipation (CC)

H. Parkman, D. Dubois, J. Johanson, 2000 .

Prucalopride (PRU) significantly improves patient (PT) quality of life (QOL) and satisfaction level in chronic constipation (CC)

P. Marquis, D. Dubois, J. Johanson, 2000 .

Antisense inhibition of ICAM-1 expression as therapy provides insight into basic inflammatory pathways through early experiences in IBD

P. Miner, J. Philpott, 2008, Expert opinion on biological therapy.

A Phase II dose ranging, double‐blind, placebo‐controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left‐sided ulcerative colitis

E. Chuang, P. Miner, M. Wedel, 2006, Alimentary pharmacology & therapeutics.

Compositions et methodes de traitement de la pochite

P. Miner, M. Wedel, 2004 .

Epitope-specific immunotherapy targeting CD4-positive T cells in coeliac disease: two randomised, double-blind, placebo-controlled phase 1 studies.

R. Xavier, J. Sidney, A. Sette, 2017, The lancet. Gastroenterology & hepatology.

Su1214 Efficacy and Safety of Plecanatide in the Treatment of Chronic Idiopathic Constipation (CIC): Results From a Multicenter Phase III Study (Study-03)

P. Miner, B. Hickey, L. Barrow, 2016 .

Characteristics of conjugated bile salt absorption by hamster jejunum.

S. Gordon, P. Miner, F. Kern, 1971, Biochimica et biophysica acta.

Evaluation of anorectal physiology in patients with increased mast cells

P. Miner, W. Biddle, R. Libel, 1993, Digestive Diseases and Sciences.

Antisense inhibition of ICAM-1 expression as therapy provides insight into basic inflammatory pathways through early experiences in IBD.

P. Miner, J. Philpott, 2008, Expert opinion on biological therapy.

Spironolactone‐ and Canrenone‐Induced Changes in Hepatic (Na+, K+)ATPase Activity, Surface Membrane Cholesterol and Phospholipid, and Fluorescence Polarization in the Rat

P. Miner, Michael Sneller, S. Crawford, 2007, Hepatology.

Effect of Treatment on the Risk of Viral Infections in Inflammatory Bowel Disease.

P. Miner, 2019, Clinical Gastroenterology and Hepatology.

Evidence‐based treatment of frequent heartburn: The benefits and limitations of over‐the‐counter medications

R. Gibb, P. Miner, J. Mcrorie, 2014, Journal of the American Association of Nurse Practitioners.

Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24‐h intragastric acidity and oesophageal acid exposure: a randomized study in gastro‐oesophageal reflux disease patients with a history of nocturnal heartburn

J. Ieni, J. Xiang, P. Miner, 2010, Alimentary pharmacology & therapeutics.

Determination of serum antibodies to Clostridium difficile toxin B in patients with inflammatory bowel disease.

T. Ali, J. Ballard, P. Miner, 2012, Gastroenterology & hepatology.

Comparison of the effects of intravenously and orally administered esomeprazole on acid output in patients with symptoms of gastro‐oesophageal reflux disease

D. Metz, M. Sostek, D. Heuman, 2005, Alimentary Pharmacology and Therapeutics.

Dig Dis Sci (2011) 56:2639–2645 DOI 10.1007/s10620-011-1801-0 ORIGINAL ARTICLE Long-Term Safety and Effectiveness of Lubiprostone, a Chloride Channel (ClC-2) Activator, in Patients with Chronic Idiopathic

H. Parkman, A. Lembo, J. Johanson, 2022 .

Relation between rectal sensation and anal function in normal subjects and patients with faecal incontinence.

N. Read, P. Miner, W. Sun, 1990, Gut.

The role of transient internal sphincter relaxation in faecal incontinence?

N. Read, P. Miner, W. Sun, 1990, International Journal of Colorectal Disease.

Delayed rectal sensation with fecal incontinence. Successful treatment using anorectal manometry.

P. Miner, W. D. Buser, William D. Buser, 1986, Gastroenterology.

The effect of ethanol on hepatic sodium plus potassium activated adenosine triphosphatase activity in the rat

P. Miner, R. Ricci, S. Crawford, 1981 .

Value of radiopaque markers in identifying partial small bowel obstruction.

P. Miner, L. A. Harrison, P. Johnson, 1996, Gastroenterology.

Failure of a motilin receptor agonist (ABT‐229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double‐blind placebo‐controlled trial

N. Talley, W. Snape, I. Fumagalli, 2000, Alimentary pharmacology & therapeutics.

The basis for the decreased response to proton pump inhibitors in gastro‐oesophageal reflux disease patients without erosive oesophagitis

M. Robinson, P. Miner, S. Sloan, 2003, Alimentary pharmacology & therapeutics.

A single dose of ranitidine 150 mg modulates oesophageal acid sensitivity in patients with functional heartburn

P. Miner, H. Proskin, S. Rodriguez-Stanley, 2004, Alimentary pharmacology & therapeutics.

Plecanatide for the treatment of constipation-predominant irritable bowel syndrome

P. Miner, 2020, Expert review of gastroenterology & hepatology.

Intragastric acidity and omeprazole exposure during dosing with either PA32540 (enteric‐coated aspirin 325 mg + immediate‐release omeprazole 40 mg) or enteric‐coated aspirin 325 mg + enteric‐coated omeprazole 40 mg – a randomised, phase 1, crossover study

P. Miner, J. Fort, Y. Zhang, 2013, Alimentary pharmacology & therapeutics.

Effect of naproxen on gastric acid secretion and gastric pH

P. Miner, S. Rodriguez-Stanley, N. Redinger, 2006, Alimentary pharmacology & therapeutics.

Efficacy of Rabeprazole in the Treatment of Symptomatic Gastroesophageal Reflux Disease

P. Kahrilas, J. Johanson, P. Miner, 2005, Digestive Diseases and Sciences.

Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.

D. Castell, R. Tutuian, M. Sostek, 2006, Clinical therapeutics.

Safety aspects and rational use of a naproxen + esomeprazole combination in the treatment of rheumatoid disease

P. Miner, D. N. Roberts, 2011, Drug, healthcare and patient safety.

Clinical trial: evaluation of gastric acid suppression with three doses of immediate‐release esomeprazole in the fixed‐dose combination of PN 400 (naproxen/esomeprazole magnesium) compared with naproxen 500 mg and enteric‐coated esomeprazole 20 mg: a randomized, open‐label, Phase I study in healthy

M. Sostek, P. Miner, J. Plachetka, 2010, Alimentary pharmacology & therapeutics.

Novel targets identified in gene expression profiles from patients with inflammatory bowel disease: O-0013

P. Alex, S. Turner, I. Dozmorov, 2007 .

Esophageal Visceral Sensitivity to Bile Salts in Patients with Functional Heartburn and in Healthy Control Subjects

P. Miner, S. Rodriguez-Stanley, S. Zubaidi, 2005, Digestive Diseases and Sciences.

Evaluation of esophageal sensation.

S. Nusrat, P. Miner, 2014, Gastrointestinal endoscopy clinics of North America.

New developments in gastroesophageal reflux disease diagnosis and therapy

T. Ali, P. Miner, 2008, Current opinion in gastroenterology.

Ranitidine 150 MG rapidly increases pain threshold and decreases symptom severity with acid infusion in patients with functional heartburn

A. Ciociola, P. Miner, H. Proskin, 2003 .

Review article: relief of symptoms in gastric acid‐related diseases – correlation with acid suppression in rabeprazole treatment

P. Miner, 2004, Alimentary pharmacology & therapeutics.

Dose-dependent effects of lesogaberan on reflux measures in patients with refractory gastroesophageal reflux disease: a randomized, placebo-controlled study

J. Pandolfino, D. Silberg, M. Ruth, 2014, BMC Gastroenterology.

Randomised clinical trial: the 5‐HT4 agonist revexepride in patients with gastro‐oesophageal reflux disease who have persistent symptoms despite PPI therapy

P. Malfertheiner, N. Shaheen, M. Ruth, 2015, Alimentary pharmacology & therapeutics.

Cisapride inhibits meal‐stimulated gastric acid secretion and post‐prandial gastric acidity in subjects with gastro‐oesophageal reflux disease

M. Robinson, P. Miner, S. Rodriguez-Stanley, 2002, Alimentary pharmacology & therapeutics.

Time esophageal pH < 4 overestimates the prevalence of pathologic esophageal reflux in subjects with gastroesophageal reflux disease treated with proton pump inhibitors

G. Triadafilopoulos, J. Gardner, M. Robinson, 2008, BMC gastroenterology.

Plecanatide, a Novel Uroguanylin Analog: A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Evaluate Efficacy and Safety in Patients With Irritable Bowel Syndrome With Constipation (IBS-C): 1831

K. Shailubhai, W. Koltun, R. Deluca, 2014 .

925g Plecanatide, a Novel Guanylate Cyclase-C (GC-C) Receptor Agonist, is Efficacious and Safe in Patients with Chronic Idiopathic Constipation (CIC): Results from a 951 Patient, 12 Week, Multi-Center Trial

D. Drossman, M. Camilleri, K. Shailubhai, 2013 .

Neurotrophin-3 Improves Functional Constipation

D. Drossman, J. Cedarbaum, N. Stambler, 2003, American Journal of Gastroenterology.

Factors influencing the relapse of patients with inflammatory bowel disease.

P. Miner, 1997, The American journal of gastroenterology.

Pilot, Randomized, Blinded, Placebo-Controlled Trial Investigating the Correlation Between Acid Control and Heartburn Relief with 14 Days of Esomeprazole Treatment

D. Johnson, P. Katz, C. Pollack, 2018, Advances in Therapy.

Intragastric acid control in non‐steroidal anti‐inflammatory drug users: comparison of esomeprazole, lansoprazole and pantoprazole

D. Silberg, P. Miner, J. Goldstein, 2006, Alimentary pharmacology & therapeutics.

Subjective, laryngoscopic, and acoustic measurements of laryngeal reflux before and after treatment with omeprazole.

J. Young, J. Searl, P. Miner, 1996, Journal of voice : official journal of the Voice Foundation.

Intermittent gastric outlet obstruction from a pedunculated gastric polyp.

P. Miner, M. McPhee, J. Harri, 1982, Gastrointestinal endoscopy.

Effects of antacid formulation on postprandial oesophageal acidity in patients with a history of episodic heartburn

A. Ciociola, M. Robinson, P. Miner, 2002, Alimentary pharmacology & therapeutics.

Psyllium is superior to docusate sodium for treatment of chronic constipation

Miner, M. Robinson, P. Miner, 1998, Alimentary pharmacology & therapeutics.

Evaluation of antibiotic-associated diarrhea with a latex agglutination test and cell culture cytotoxicity assay for Clostridium difficile.

N. Greenberger, P. Miner, W. Biddle, 1989, American Journal of Gastroenterology.

5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided ulcerative colitis.

N. Greenberger, P. Miner, M. Mcphee, 1988, Gastroenterology.

Interferon-b-1a in Active Moderate to Severe Ulcerative Colitis: Efficacy and Safety from a Phase IIa Multicenter Study: 1216

P. Mannon, R. Panaccione, P. Miner, 2010 .

Safety Analysis from a Phase IIa Multicenter Study with Interferon-β-1a in Active Moderate to Severe Ulcerative Colitis: 1189

S. Zakko, P. Miner, F. Cataldi, 2010 .

Secondary Efficacy Analysis from a Phase IIa Multicenter Study with Interferon-β-1a for Induction of Clinical Response in Active Moderate to Severe Ulcerative Colitis: 1274

P. Mannon, M. Lukáš, P. Miner, 2010 .

Is the partial Mayo score predictive of efficacy in ulcerative colitis trials? Comparison between the partial and the total Mayo score from a study with Interferon-B-1a in ulcerative colitis.

P. Mannon, J. O'Gorman, S. Zakko, 2011 .

Improvement in work productivity

P. Mannon, P. Miner, F. Cataldi, 2011 .

Heartburn severity can predict pathologic oesophageal reflux in gastro‐oesophageal reflux disease patients treated with a proton‐pump inhibitor

J. Gardner, M. Robinson, P. Miner, 2003, Alimentary pharmacology & therapeutics.

Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro‐oesophageal reflux disease treated with a proton pump inhibitor

M. Robinson, P. Miner, S. Sloan, 2003, Alimentary pharmacology & therapeutics.

Omeprazole Can Prevent the Gastroduodenal Mucosal Injury Associated with Combined Use of Clopidogrel and Aspirin: 123

P. Lapuerta, M. Goldsmith, D. Azarnoff, 2008 .

P. Miner, Ying Zhang, J. Fort, 2013, Alimentary pharmacology & therapeutics.

The effects of changing temperature correction factors on measures of acidity calculated from gastric and oesophageal pH recordings

M. Robinson, P. Miner, S. Sloan, 2006, Alimentary pharmacology & therapeutics.

Drug, Healthcare and Patient Safety Dovepress Safety Aspects and Rational Use of a Naproxen + Esomeprazole Combination in the Treatment of Rheumatoid Disease

P. Miner, David N Roberts, 2022 .

Efficacy and safety of plecanatide in treating constipation predominant irritable bowel syndrome

P. Miner, 2018, Expert opinion on pharmacotherapy.